EVERFRONT BIOTECH INC.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
1. EF-001 (Cerebraca® Wafer)
2. EF-009 Wafer
3. HK-001
4. EF-031
5. TSCA-001
6. EF-011
2. EF-009 Wafer
3. HK-001
4. EF-031
5. TSCA-001
6. EF-011
The content above was translated by Ai
Founded Year
2010
Unified Business No.
53197299
Status
Active
Number of Employees
13
Total Paid-in
Capital
514,154,500 (NT$)
Location of Company
Taiwan
, New Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Everfront Biotech Inc. (EFB) was found by the President Ho-Ching Chen and Chairman Dr. Pei-Wen Chou, and invited a group of distinguished researchers to form a research team for new drug discovery and development. This team included Professor Shinn-Zong Lin, the Superintendent of Hualien Tzu Chi Hospital, Professor Horng-Jyh Harn, the associate vice president of Bioinnovation Center in Tzu Chi foundation, Professor Tzyy-Wen Chiou from Dong-Hua University, and Dr. Tza-Zen Chaung. The establishment of this team marked a new era for the company’s drug discovery and development.
We are developing small molecules that have the potential to bring safe and effective treatments for the patients with cancers, neuronal degenerative diseases and rare diseases. Our team is specialized in pre-clinical study design, CMC；Chemistry, Manufacturing, and Control, IND-submission, and the clinical trial design and conduction.
Up to now, total three clinical trials are performing in Taiwan under the approval of USFDA and TFDA. Besides, five more products are under the pre-clinical status. Progressively, we are devoted in developing the technology that have commercial application potentials to help the people with urgent medical needs.
We are developing small molecules that have the potential to bring safe and effective treatments for the patients with cancers, neuronal degenerative diseases and rare diseases. Our team is specialized in pre-clinical study design, CMC；Chemistry, Manufacturing, and Control, IND-submission, and the clinical trial design and conduction.
Up to now, total three clinical trials are performing in Taiwan under the approval of USFDA and TFDA. Besides, five more products are under the pre-clinical status. Progressively, we are devoted in developing the technology that have commercial application potentials to help the people with urgent medical needs.
The content above was translated by Ai
